The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -18.33 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.73 — no flag raisedOK
- Earnings quality 74/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as ROCKWELL MEDICAL, INC. reports it. History and quarterly detail are in the app.
- Concentrate Products Sales$68.9M
- License Fees$325K
Leadership changes
From ROCKWELL MEDICAL, INC.'s own filings, the day they're filed.
- Joseph H. Dawson · director · appointmenteff. 2025-11-17
- Andrea Heslin Smiley · Directors · departureeff. 2025-11-17
- Heather Hunter · President · appointmenteff. 2025-09-23
Latest filings
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ROCKWELL MEDICAL, INC., every answer cited🔒
- The Intelligence Brief — added when ROCKWELL MEDICAL, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.